Location History:
- Media, PA (US) (2017 - 2019)
- Therwil, CH (2019 - 2020)
Company Filing History:
Years Active: 2017-2020
Title: Daniel Ricklin: Innovator in Pharmaceutical Research
Introduction
Daniel Ricklin, based in Media, PA, is a notable inventor who has made significant contributions to the field of pharmaceutical research. With a total of five patents to his name, he has focused extensively on developing compounds that enhance the pharmacokinetic properties of peptides, particularly those that inhibit complement activation.
Latest Patents
Among his latest patents, Ricklin has developed innovative compstatin analogs that showcase improved pharmacokinetic properties. These compounds comprise peptides capable of binding to the C3 protein and inhibiting complement activation. Notable features of his patented compounds include enhancements to their binding affinity, solubility in aqueous liquids, plasma stability, in vivo retention, and bioavailability compared to unmodified compstatin peptides under equivalent conditions. His work facilitates the creation of pharmaceutical compositions and outlines methods for utilizing these compounds effectively.
Ricklin's other recent patent further enhances the potency of compstatin analogs. This invention includes a modified compstatin peptide that demonstrates improved binding affinity to C3 and its fragments (C3b and C3c). The modifications are focused on increasing the plasma stability and residence time of the peptide, thus advancing the potential therapeutic applications of these compounds.
Career Highlights
Daniel Ricklin has established his career at the University of Pennsylvania, where he engages in groundbreaking research that pushes the boundaries of pharmaceutical science. His expertise in peptide technology and complement system biology has positioned him as a leading figure in his field.
Collaborations
Throughout his career, Ricklin has collaborated with esteemed colleagues, including John D. Lambris and Hongchang Qu. These partnerships have enabled him to expand the scope of his research and contribute to advancements within the scientific community.
Conclusion
In conclusion, Daniel Ricklin's innovative work on compstatin analogs has significant implications for the development of new therapeutic strategies. Through his patents and collaborative efforts, he continues to enhance our understanding of complement activation and its inhibition, solidifying his reputation as a forward-thinking inventor in the pharmaceutical domain.